Drug Trial Radar · NCT00003490
Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Dec 4, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Planned (sponsor's estimate)
Start
Oct 1998
Primary completion
Not stated
Study completion Aug 2003
Sponsor
- Lead sponsor
- The Cleveland ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 21, 2004
Design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. GM-CSF may make cancer cells more sensitive to the effects of chemotherapy. Combining more than one drug with GM-CSF may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, consisting of cyclophosphamide plus vincristine, following GM-CSF in treating patients with multiple myeloma that has not responded to previous treatment.
Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
Interventions
sargramostimBiological
cyclophosphamideDrug
prednisoneDrug
vincristine sulfateDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cleveland Clinic Cancer Center
Cleveland, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.